(UroToday.com) While cisplatin-based chemotherapy is an accepted first-line treatment for patients with advanced or metastatic urothelial carcinoma and immune checkpoint inhibitors (CPI) are used in both the first-line setting for patients who are cisplatin-ineligible and as maintenance or second-line therapy in those who have previously received cisplatin-based chemotherapy, there are limited treatment options past these. Recently, sacituzumab govitecan, an antibody-drug conjugate consisting of an anti–Trop-2 monoclonal antibody coupled to SN-38 (an active metabolite of irinotecan, a topoisomerase I inhibitor), has been utilized in this population.